Leeds Cancer Centre at St. James's University Hospital
10
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients
Role: collaborator
An International Study on Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer
Role: collaborator
Revision of the EORTC QLQ-BN20 Questionnaire
Role: collaborator
The European Palliative Care Cancer Symptom Study (EPCCS)
Role: collaborator
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
Role: lead
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
Role: lead
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Role: lead
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Role: lead
Study of Families With Melanoma
Role: lead
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
Role: lead
All 10 trials loaded